Harbour Investments Inc. Has $650,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Harbour Investments Inc. lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 9,926 shares of the company’s stock after acquiring an additional 1,121 shares during the period. Harbour Investments Inc.’s holdings in AstraZeneca were worth $650,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of AZN. Corient Private Wealth LLC increased its position in AstraZeneca by 4.7% during the fourth quarter. Corient Private Wealth LLC now owns 197,257 shares of the company’s stock worth $12,642,000 after acquiring an additional 8,894 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in shares of AstraZeneca by 4.9% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 146,769 shares of the company’s stock worth $9,616,000 after purchasing an additional 6,853 shares in the last quarter. Choate Investment Advisors grew its position in shares of AstraZeneca by 69.6% during the 4th quarter. Choate Investment Advisors now owns 9,873 shares of the company’s stock worth $647,000 after purchasing an additional 4,053 shares in the last quarter. Natixis Advisors LLC increased its holdings in shares of AstraZeneca by 5.1% during the fourth quarter. Natixis Advisors LLC now owns 2,060,198 shares of the company’s stock worth $134,984,000 after purchasing an additional 99,383 shares during the period. Finally, Frank Rimerman Advisors LLC raised its position in shares of AstraZeneca by 30.7% in the fourth quarter. Frank Rimerman Advisors LLC now owns 12,748 shares of the company’s stock valued at $835,000 after buying an additional 2,992 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AZN shares. Morgan Stanley initiated coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Down 1.0 %

Shares of AZN stock opened at $76.32 on Thursday. AstraZeneca PLC has a fifty-two week low of $62.75 and a fifty-two week high of $87.68. The stock’s fifty day moving average price is $72.47 and its two-hundred day moving average price is $72.16. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The company has a market cap of $236.68 billion, a PE ratio of 33.77, a P/E/G ratio of 1.42 and a beta of 0.41.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be issued a dividend of $1.03 per share. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. AstraZeneca’s payout ratio is 91.15%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.